Analytical Data
-
Gene name
HLA-G
- Application
-
Alternative Names
HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G
-
Species
Human
-
Source
E. coli
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P17693-1
-
Expression Region
G25-A206
-
Molecular Weight
23-26 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-G is a unique class Ib human leukocyte antigen that plays a critical role in immune regulation, particularly in pregnancy and transplantation tolerance. Unlike classical HLA molecules, HLA-G is characterized by its restricted expression patterns and the ability to inhibit natural killer (NK) cell activity and T-cell responses, contributing to the protection of fetal tissues from maternal immune attack. The study of recombinant HLA-G protein has gained momentum due to its potential therapeutic applications in various clinical settings, including organ transplantation, autoimmune diseases, and cancer immunotherapy. Researchers are increasingly interested in understanding the structure-function relationship of HLA-G and its interactions with immune cells to harness its immunomodulatory properties. By producing HLA-G as a recombinant protein, scientists aim to investigate its biological functions, develop diagnostic tools, and explore its use as a biomarker for pregnancy complications and immune-related disorders. Additionally, recombinant HLA-G can be utilized in preclinical studies to evaluate its therapeutic potential, paving the way for innovative treatments aimed at enhancing immune tolerance and mitigating unwanted immune responses in diverse medical contexts.
